Set your alerts for this stock has a history of 100% spikes, price up premarket on no news?
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small...
Yesterdays gainers are quickly forgotten, up 170% on the 4/22/19 and loses drops 50% on 4/23/19 on news of new offering. Despite this a great opportunity may still exist in the name, tomorrow there is still scheduled call to announce developments in FDA approval and possible positive results from its new lung cancer drug.
Is $MBRX- The Best Biotech with the most upside Potential
Just announced a major breakthrough in its effort to develop a new cancer treatment that selectively kills highly resistant tumors. Company has a relatively small OS under 25 Mil and float under 15 Mil . The company is working with the most prestigious cancer centers to treat a broader range of the...
$MBRX double fib wedge re-trace down to 50% before potential impulse move back up on the long side. High volume price spike could see to another re-test of $3.25-$3.30 range without breaking previous highs. Time will tell if/when gap fills @ $1.65-$1.75 for possible bounce towards high $2.00 - low $3.00 range.
As we see, a correction is happening, but I think it will end within the next two hours.
Then of course, the price will follow the initial trend, and we have our long position. I entered a small position already, what is a bit sketchy, but I think it is worth it.
-EMA 200 says: buy
-Main trend says: buy
-past patterns say: buy
-higher highs and higher lows means:...
As I forecasted yesterday, MBRX has all the fundamentals and technicals in place. Well above the EMA, closing higher than the open, and having a healthy resistance upwards. I estimated 2.60 a little too soon but tomorrow the 28th will certainly hit 2.60 as the trendline continues.